Modified antibodies of induced anti-idiotype reaction enhancement

An anti-idiotype and reaction technology, applied in the field of modified immunoglobulin and its vaccine composition, can solve the problem of limited tendency of anti-idiotype reaction and the like

Inactive Publication Date: 2001-12-19
欧洲细胞技术有限公司
View PDF20 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

One of the reasons for the failure is that although the Ab1 that produces the anti-idiotypic response is exogenous, since the antibody molecules are all very similar, they are very similar to their own molecules, and the body's propensity to produce an anti-idiotypic response to its own molecules is limited

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Modified antibodies of induced anti-idiotype reaction enhancement
  • Modified antibodies of induced anti-idiotype reaction enhancement
  • Modified antibodies of induced anti-idiotype reaction enhancement

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0116] Alternatively, disulfide-forming cysteines may be replaced with non-sulfhydryl-containing atypical amino acids or chemical amino acid analogs (such as, but not limited to, conventional protein synthesis methods). Atypical amino acids include: D-amino acids of typical amino acids, α-aminobutyric acid, 4-aminobutyric acid, Abu, 2-aminobutyric acid, γ-Abu, ε-Ahx, -aminocaproic acid, Aib, 2-aminoisobutyric acid Butyric acid, 3-aminopropionic acid, ornithine, norleucine, norvaline, hydroxyproline, sarcosine, citrulline, tert-butylglycine, tert-butylalanine, phenyl Glycine, cyclohexylalanine, β-alanine, fluoro-amino acids such as designed β-methyl amino acids, Cα-methyl amino acids, Nα-methyl amino acids, amino acid analogs. Also, amino acids can be right-handed or left-handed. In alternative embodiments, disulfide bond forming amino acid residues may be deleted.

[0117] In specific embodiments, disulfide bond-forming amino acid residues in the variable region of the heavy...

Embodiment 7

[0364] Example 7 Expression of Synthetic Modified Antibody Containing HMFG-1 Sequence

[0365]Anti-idiotypic antibodies that immunospecifically bind to HMFG-1 antibodies were constructed. HMFG-1 is an antibody known to bind polymorphic epidermal mucin (PEM) (Stewart et al., 1990, Journal of Clinical Oncology 8: 1941-50; Kosmas et al., 1994, Cancer 73: 3000-3010 ). The antigenic determinant sequence ProAspThrArgPro of PEM is inserted into the variable region of the antibody by the method of the present invention. This short sequence is a highly immunogenic region in human polymorphic epidermal mucin (Gendler et al., 198, J. Biol. Chem. 163: 12820-12823). The 27A-27E (SerLeuLeuTyrSer) residues of HMFG-1 (Table 6) were replaced with ProAspThrArgPro by the oligonucleotide synthesis method described in Section 6, see FIG. 10 . Using the known gene sequence of the light and heavy chain variable regions of the HMFG-1 antibody, an anti-idiotypic antibody that immunospecifically bin...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to the modification of immunoglobulin molecules in which one or more cysteine ​​residues in the variable region which form intrachain disulfide bonds are replaced by amino acids which do not contain a sulfhydryl group and thus do not form disulfide bonds. The ability of these modified immunoglobulin molecules to induce an anti-idiotypic response is enhanced. The present invention further provides a method for treating or preventing tumors and/or infectious diseases using the modified immunoglobulin of the present invention.

Description

[0001] Cross-references to related applications: [0002] This application claims the benefit of two applications, Provisional Application No. 60 / 065,716, filed November 14, 1997, and Provisional Application No. 60 / 081,403, filed April 10, 1998, which are incorporated herein in their entirety Incorporated by reference. 1. Field of invention: [0003] The present invention relates to modified immunoglobulins and vaccine compositions thereof, wherein one or more cysteine ​​residues in the variable region that form an intrachain disulfide bond are replaced with an amino acid that does not contain a sulfhydryl group, thereby not forming disulfide bond. The invention also relates to the use of the vaccine compositions of the invention to treat or prevent certain diseases and disorders, especially cancer and infectious diseases. 2. Background of the invention [0004] 2.1 Immunoglobulin structure [0005] The basic unit of immunoglobulin structure is a complex of four polypepti...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C12N15/09A61K38/00A61K39/00A61K39/395A61K48/00A61P31/00A61P31/04A61P31/18A61P35/00A61P37/02C07K7/18C07K16/00C07K16/08C07K16/12C07K16/20C07K16/30C07K16/42C12N5/10G01N33/574
CPCA61K38/00A61K39/00A61K2039/505C07K7/18C07K16/00C07K16/3046C07K16/4266C07K2317/565C07K2318/10C07K2319/00A61P31/00A61P31/04A61P31/18A61P35/00A61P37/02Y02A50/30A61K39/395
Inventor R·M·布尔克
Owner 欧洲细胞技术有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap